

TRANSCRIPTIONAL PROPERTIES OF MEOX2

BY

Mona M.T. Friesen

A Thesis submitted to
the Faculty of Graduate Studies
In Partial Fulfillment of the Requirements for the Degree of

MASTER OF SCIENCE

Department of Biochemistry and Medical Genetics
Faculty of Medicine
University of Manitoba
Division of Stroke and Vascular Disease
St. Boniface General Hospital Research Centre
Winnipeg, Manitoba

© Mona M.T. Friesen, August 23, 2005

TRANSCRIPTIONAL PROPERTIES OF MEOX2

BY

Mona M.T. Friesen

A Thesis submitted to
the Faculty of Graduate Studies
In Partial Fulfillment of the Requirements for the Degree of

MASTER OF SCIENCE

Department of Biochemistry and Medical Genetics
Faculty of Medicine
University of Manitoba
Division of Stroke and Vascular Disease
St. Boniface General Hospital Research Centre
Winnipeg, Manitoba

© Mona M.T. Friesen, August 23, 2005



Library and
Archives Canada

Bibliothèque et
Archives Canada

0-494-08854-0

Published Heritage
Branch

Direction du
Patrimoine de l'édition

395 Wellington Street
Ottawa ON K1A 0N4
Canada

395, rue Wellington
Ottawa ON K1A 0N4
Canada

Your file *Votre référence*

ISBN:

Our file *Notre référence*

ISBN:

NOTICE:

The author has granted a non-exclusive license allowing Library and Archives Canada to reproduce, publish, archive, preserve, conserve, communicate to the public by telecommunication or on the Internet, loan, distribute and sell theses worldwide, for commercial or non-commercial purposes, in microform, paper, electronic and/or any other formats.

The author retains copyright ownership and moral rights in this thesis. Neither the thesis nor substantial extracts from it may be printed or otherwise reproduced without the author's permission.

AVIS:

L'auteur a accordé une licence non exclusive permettant à la Bibliothèque et Archives Canada de reproduire, publier, archiver, sauvegarder, conserver, transmettre au public par télécommunication ou par l'Internet, prêter, distribuer et vendre des thèses partout dans le monde, à des fins commerciales ou autres, sur support microforme, papier, électronique et/ou autres formats.

L'auteur conserve la propriété du droit d'auteur et des droits moraux qui protègent cette thèse. Ni la thèse ni des extraits substantiels de celle-ci ne doivent être imprimés ou autrement reproduits sans son autorisation.

In compliance with the Canadian Privacy Act some supporting forms may have been removed from this thesis.

Conformément à la loi canadienne sur la protection de la vie privée, quelques formulaires secondaires ont été enlevés de cette thèse.

While these forms may be included in the document page count, their removal does not represent any loss of content from the thesis.

Bien que ces formulaires aient inclus dans la pagination, il n'y aura aucun contenu manquant.


Canada

THE UNIVERSITY OF MANITOBA
FACULTY OF GRADUATE STUDIES

COPYRIGHT PERMISSION

“Transcriptional Properties of Meox2”

BY

Mona M.T. Friesen

**A Thesis/Practicum submitted to the Faculty of Graduate Studies of The University of
Manitoba in partial fulfillment of the requirement of the degree
Of
MASTER OF SCIENCE**

Mona M.T. Friesen © 2005

Permission has been granted to the Library of the University of Manitoba to lend or sell copies of this thesis/practicum, to the National Library of Canada to microfilm this thesis and to lend or sell copies of the film, and to University Microfilms Inc. to publish an abstract of this thesis/practicum.

This reproduction or copy of this thesis has been made available by authority of the copyright owner solely for the purpose of private study and research, and may only be reproduced and copied as permitted by copyright laws or with express written authorization from the copyright owner.

TABLE OF CONTENTS

ABSTRACT	i
ACKNOWLEDGEMENTS	ii
LIST OF FIGURES	iii
LIST OF TABLES	iv
LIST OF ABBREVIATIONS	v
A) LITERATURE REVIEW	1
I) Cardiovascular disease	1
II) The cell cycle	2
1. Five phases	2
2. Cell cycle checkpoints	3
III) Homeobox Genes	6
1. Isolation and molecular characterization	6
2. Role of homeobox genes in human development and disease	7
3. Cellular role of homeobox genes	8
IV) Mesenchyme homeobox genes	8
1. Conservation of <i>Meox</i> genes during evolution	8
2. <i>Meox1</i> and <i>Meox2</i> expression during embryogenesis	10
i) <i>Meox1</i> expression in the somites	10
ii) <i>Meox2</i> expression in the somites	11
iii) <i>Meox2</i> expression during cardiogenesis	12
iv) <i>Meox2</i> is required for Pax activation during limb muscle development	13
3. <i>Meox1</i> and <i>Meox2</i> expression in the adult	14
4. <i>Meox2</i> regulation of cell cycle progression	14
i) Induction of a G_0/G_1 cell cycle arrest	14
ii) Requirement of the CDKI p21	17
iii) Involvement of other CDKIs	17
5. <i>Meox2</i> induction of apoptosis	18
6. <i>Meox2</i> block of cellular migration	19
7. <i>Meox2</i> as a possible therapeutic target	19
V) p21 Cyclin Dependent Kinase Inhibitor	21
1. Isolation and characterization of p21	21

2. The role of p21 in regulating apoptosis	21
3. The role of p21 in modulating the cell cycle	22
4. Regulation of p21 transcription by homeodomain proteins	
i) Cdx2 and HoxA10	22
ii) Meox2	23
VI) Bapx1	23
1. Role of Bapx1 during sclerotome differentiation	23
2. Bapx1 transcriptional regulation	26
i) Synergistic activation by Pax1/9 and Meox1/2	26
ii) Putative genetic hierarchy of <i>Bapx1</i> regulation	26
B) RATIONALE	28
C) MATERIALS AND METHODS	30
I) Materials	30
II) Methods	31
1. Plasmids and reporter constructs	31
i) EGFP tagged Meox1/2 mammalian expression vectors	31
ii) FLAG epitope tagged Meox1/2 mammalian expression vectors	31
iii) <i>p21</i> and <i>Bapx1</i> promoter luciferase reporter constructs	34
iv) pcDNA3 Meox2 expression vectors	35
v) pMal Meox2 bacterial fusion protein expression vectors	36
2. Site directed mutagenesis and deletions	36
3. Cell lines	37
i) NIH/3T3 mouse fibroblast cell line	37
ii) 293-HEK human embryonic kidney cell line	37
iii) Plasmid DNA transfections	37
4. Western Blot Analysis	38
5. Immunocytochemistry	38
6. Luciferase Reporter Gene Assays	39
7. Affinity purification of recombinant Meox2-maltose binding protein (MBP) fusion protein	40
8. Nuclear Extract Preparation	41
9. Non-radioactive electrophoretic mobility shift assays	42
i) Probe annealing	42
ii) Assays	42
D) RESULTS	44
I) Expression of epitope tagged Meox proteins in NIH/3T3 cells	44

II) Meox2 DNA binding dependent activation of the <i>Bapx1</i> promoter	49
III) Meox binding to the <i>Bapx1</i> promoter	56
IV) Meox DNA binding independent activation of the <i>p21</i> promoter	61
V) The carboxyl-terminal FLAG tag affects Meox2 mediated transcriptional activation	78
E) DISCUSSION	83
F) CONCLUSIONS	95
G) REFERENCES	96

ABSTRACT

Meox2 induces cell cycle arrest and it is postulated that Meox2 is required for maintaining adult vascular smooth muscle cells (VSMCs) in a quiescent state. Upon vascular injuries, such as atherosclerosis, VSMCs transform from a quiescent, contractile phenotype to a proliferative phenotype. Downregulation of Meox2 expression is observed during this phenotypic transformation.

Currently, direct Meox2 downstream targets are unknown. However, we hypothesize that Meox2 can act as a transcription factor. The aim of this investigation was to examine the transcriptional properties of Meox2.

Our results demonstrated that Meox1 and Meox2 do not require binding to DNA to activate the *p21* promoter. Conversely, *Bapx1* promoter activation is dependent on Meox2-DNA interaction. This study is the first to report that the Meox1 and Meox2 proteins regulate the same downstream target genes and that the mechanism of this regulation is promoter-specific.

ACKNOWLEDGEMENTS

The following work could not have been accomplished without the help and support of many people and organizations. First of all, I am very grateful for the training I have received from my advisor, Dr. Jeffrey Wigle. I also appreciated the contributions of all the Wigle lab members to this work and their friendship over the years. My committee members have also been very instrumental in ensuring my success in the Masters program: Thank you very much to Dr. Nasrin Mesaeli and Dr. David Eisenstat for your suggestions and support. I have also been fortunate to have received funding and scholarships from various organizations during the course of my studies, including the Manitoba Health Research Council, the Department of Biochemistry and Medical Genetics and the University of Manitoba Students Union. I would also like to extend special thanks to the members of the Division of Stroke and Vascular Disease and the St. Boniface General Hospital Research Centre.

De plus, j'aimerais remercier mon cher Eric. Sans toi je n'aurai pas pu poursuivre ce programme jusqu'à ça fin. Tu as été là avec moi à chaque étape, ton encouragement et ton amour m'ont souvent porté à travers les temps les plus difficiles. Je te remercie infiniment.

LIST OF FIGURES

- Figure 1: Cyclin regulation of cell cycle progression
Figure 2: The Homeodomain
Figure 3: Alignment of murine Meox1 and Meox2 protein sequences
Figure 4: Meox2 protein structure
Figure 5: Sequence conservation of Meox2 during evolution
Figure 6: Meox2 involvement in cellular processes
Figure 7: Somitegenesis and the fate of somite cell populations
Figure 8: Schematic representation of the Meox2 proteins
Figure 9: Subcellular distribution of exogenously expressed Meox proteins
Figure 10: Similar expression levels of the different Meox proteins in HEK293 cells
Figure 11: Meox2 activates the *Bapx1* promoter
Figure 12: Meox2 DNA-binding dependent activation of the *Bapx1* promoter
Figure 13: Meox2 activation of *Bapx1* promoter is greatly decreased by the DNA binding domain mutation
Figure 14: Meox1-FLAG binds to a consensus site within the *Bapx1* promoter
Figure 15: Meox2-FLAG does not bind to the Meox1 DNA consensus binding site in the *Bapx1* promoter
Figure 16: Purification of recombinant MBP-Meox2-FLAG protein
Figure 17: *p21* promoters
Figure 18: Meox1/2 activate the 2.4 kb *p21* promoter
Figure 19: DNA binding independent and p53 independent activation of the *p21* promoter by Meox1/2
Figure 20: DNA binding independent activation of the *p21* promoter by Meox2
Figure 21: Dose dependent activation of the *p21* promoter by Meox2
Figure 22: The amino terminal region of Meox2 activates the *p21* promoter
Figure 23: Meox2 induces *p21* transcription by acting as a transcriptional activator
Figure 24: The homeodomain and carboxyl-terminal regions of Meox2 do not require the presence of consensus homeodomain binding sequences to activate the *p21* promoter
Figure 25: Meox2 activates regions of the truncated *p21* promoter lacking the homeodomain binding consensus sequences
Figure 26: Meox2 does not activate transcription from the 850 bp *p21* promoter in NIH/3T3 cells.
Figure 27: Carboxyl terminal epitope tagging reduced the transcriptional activation of Meox2
Figure 28: *Bapx1* promoter activation using pcDNA3-Meox2
Figure 29: The carboxyl terminal FLAG epitope reduces Meox2 activation of the *p21* promoter
Figure 30: Models of Meox2 protein interactions with the *p21* promoter

LIST OF TABLES

Table 1: Cloning and mutagenesis primers

Table 2: EMSA probes

LIST OF ABBREVIATIONS

AD = Activation domain
Ad-*Meox2* = Adenovirus construct encoding *Meox2*
Ang II = (Angiotensin II)
ASK1 = Apoptosis signalling regulating kinase
BrdU = 5-bromo-2-deoxyuridine
CDK = Cyclin dependent kinase
CDKI = Cyclin dependent kinase inhibitor
Cip1 = Cdk-interacting protein 1
CNP = C-Type Natriuretic Peptide
d.p.c = Days post coitus
DBD = DNA binding domain
EGFP = Enhanced green fluorescent protein
EMSAs = Electrophoretic mobility shift assays
Eng = Engrailed
FACS = Fluorescent activated cell sorting
HEK293 = Human embryonic kidney cells
HUVECs = Human umbilical vein endothelial cells
IPTG = Isopropyl-beta-D-thiogalactopyranoside
MBP = Maltose binding protein
MEFs = Mouse embryonic fibroblasts
Mt = Mutant
NIH/3T3 = Mouse fibroblast cell line
NLS = Nuclear localization sequence
Pax = Paired box homeobox gene
Pax3 = Paired box protein
PBS = Phosphate buffered saline
PBS-T = Phosphate buffered saline with Tween
PCNA = Proliferating cellular nuclear antigen
Rb = Retinoblastoma
RD = Repressor domain
shh = Sonic hedgehog
TBS = Tris buffered saline
TBS-T = Tris buffered saline with Tween
TUNEL = TdT-mediated dUTP-fluorescein nick-end labeling
VEGF = Vascular Endothelial Growth Factor
VSMCs = Vascular smooth muscle cells
WAF1 = Wild-type p53-activated fragment

A) LITERATURE REVIEW

I) Cardiovascular disease

Adult vascular smooth muscle cells (VSMCs) are normally quiescent, contractile cells but these cells can undergo a phenotypic switch and adopt a synthetic (less differentiated), proliferative phenotype. This phenotypic switch occurs during natural biological processes such as embryonic development, responses to injury, or vessel remodeling induced by changes in tissue demands [1]. Increases in VSMC proliferation contributes to the progression of many pathological conditions such as atherosclerosis, hypertension, post-angioplasty restenosis and coronary artery transplant vasculopathy [1, 3-6]. In vasculoproliferative diseases such as restenosis, VSMC growth contributes to the stenosis of the blood vessel by forming the neointimal layer [4, 5].

The mechanisms that induce the VSMC phenotypic switch vary due to the heterogeneous nature of blood vessels within the body [1]. Signaling by both autocrine molecules such as platelet derived growth factor, fibroblast growth factor, epidermal growth factors, angiotensin II and paracrine molecules (i.e. nitric oxide and endothelin-1) secreted by adjacent endothelial cells, monocytes, fibroblasts and dendritic cells play a role in mediating the phenotypic switch [1]. As well, stimuli such as hypoxia, mechanical forces and reactive oxygen species are involved in the activation of VSMCs [1, 7-10]. A better understanding of how these signals converge to regulate VSMC cell cycle progression is identifying potential new therapeutic targets for use in the treatment of vasculoproliferative diseases. Conventional therapies largely treat the symptoms which result from an established vascular lesion rather than by targeting the underlying mechanisms involved in lesion formation [3]. Furthermore, understanding how the cell

cycle is regulated in VSMCs may also be a useful approach to prevent the vascularization of tumors which is crucial for both tumor growth and dissemination [11, 12].

Cardiomyocytes proliferate at a very low rate in the healthy adult and this low rate of proliferation cannot be induced sufficiently to regenerate the cardiac muscle lost following insults such as a myocardial infarction [13]. An understanding of how the cell cycle is controlled in cardiomyocytes could provide the basis for the development of therapies aimed at myocardial reconstitution [14-17]. Manipulating the function or level of molecules that either promote cell cycle entry or the down-regulation of molecules that inhibit cell cycle entry would be beneficial for repairing the damaged myocardium [14-17].

II) The cell cycle

1. Five phases

The cell cycle is a tightly regulated process by which a cell grows, duplicates its genomic DNA and separates into two identical daughter cells. The cell cycle includes five stages; three Gap phases (G-phases), the S-phase and the M-phase (Figure 1). Quiescent cells in the G_0 gap phase enter the G_1 phase following stimulation by mitogens or growth factors. During the G_1 phase, cells synthesize the mRNA and proteins required for duplicating their DNA during the S-phase. In the following phase, G_2 , cells produce the mRNA and protein necessary for the M-phase (mitosis). Mitosis includes karyokinesis and cytokinesis, the separation of the DNA and the daughter cells respectively.

2. Cell cycle checkpoints

Transitions through the different phases of the cell cycle are regulated by several checkpoints. These checkpoints ensure that the environment is favorable for replication by assessing positive and negative signals. Also, they ensure the sequential order of events by establishing that each step is finished before the next step begins and that DNA is faithfully replicated [18, 19]. Transition past these checkpoints is controlled by positive and negative regulators. Positive regulation is provided by the association of cyclins with, and the activation of, their respective cyclin dependent kinases (CDKs) (see Figure 1). CDK levels are constant during the different phases of the cell cycle. However, the activity of these molecules is regulated by phosphorylation and dephosphorylation by CDK-activating kinases and phosphatases respectively [20-22]. Previously, it was believed that CDKs must bind cyclins in order to be activated. Cyclin protein levels are regulated by their synthesis, degradation and nuclear transport and they exhibit a cyclic expression pattern during the cycle. [3, 23]. The activated cyclin-CDK complexes then phosphorylate other effector molecules such as histones and the retinoblastoma (Rb) pocket-proteins [3]. Recent results suggest that CDKs can also be positively regulated by cell-type specific proteins other than cyclins. Examples of such proteins are the Speedy/Ringo proteins and p35 [24-27]. These proteins do not share any homology with the cyclins but can selectively bind specific CDKs and activate them independent of cyclin binding [25, 28].

For example, the association of cyclinD-CDK4 and cyclinE-CDK2 in G₁ leads to the phosphorylation of hypo-phosphorylated Rb. Hypo-phosphorylated Rb binds to and inactivates the E2F transcription factors. Phosphorylation of Rb disassociates the Rb-E2F

complex and the free E2F then binds and activates the promoters of genes needed for entry into S-phase [29].

Negative regulation of the cell cycle is provided by CDK inhibitors (CKIs) such as p21^{WAF1/CIP1} (referred to as p21 throughout the remainder of this thesis), p27^{kip1} and p57^{kip2}. These molecules bind and inactivate the cyclin-CDK complex [30]. p21 was initially identified using cDNA subtractive hybridization of cells either expressing or not-expressing the transcription factor and tumor suppressor protein p53 [31]. Analysis of the *p21* promoter revealed that it contained two p53 consensus binding sites and electrophoretic mobility shift assays (EMSAs) showed that the p53 protein could indeed bind to these sites [31, 32]. Other transcription factors have also been shown to regulate *p21* expression. GATA-6 and Meox2 induce *p21* and subsequently induce a p21 dependent cell cycle arrest. However, they both act independently of p53 [33-35].




Figure 1: Cyclin regulation of cell cycle progression

Transition through the cell cycle is regulated by the association of specific cyclins with CDKs. Progression through the G₁ phase initially requires the interaction of cyclin D with CDKs 4 and 6 and later the association of cyclin E with CDK2. The p21 CDKI, which is induced by several transcription factors including Meox2, can block transition to the S phase of the cell cycle.

III) Homeobox Genes

1. Isolation and molecular characterization

Several genes, called homeotic genes, were found to cause transformations of one segment or organ to another in insects (homeotic transformations) [36-38]. Subsequent analysis revealed that these genes have a conserved protein coding sequence, the homeobox, which is also well conserved in orthologous genes in other species [39]. The homeobox, first described in 1984, codes for a 60 amino-acid segment (homeodomain) that is able to recognize and bind to specific DNA sequences [2, 39]. This conserved motif is composed of three major helices and a fourth small helix (Figure 2). Helices I and II are separated by a loop whereas helix II and III are separated by a turn [2]. The helix-turn-helix motif, formed by helices II and III, resembles a DNA binding motif found in many prokaryotic proteins such as the lactose and tryptophan repressors [40, 41]. However, the overall structure of the homeodomain is unique to eukaryotes [42]. Helices III and IV lie within the major groove of the DNA double helix and make intermolecular contacts with the DNA [2, 42]. Conserved residues in this domain are important for the overall three dimensional structure whereas the non-conserved residues convey binding specificity [42]. As a result, homeodomain proteins interact with specific DNA operators through their homeodomain whereas this region and other regions of homeodomain proteins mediate protein-protein interactions with accessory proteins important for transcriptional regulation, nuclear import and protein turnover [42-46].




Figure 2: The Homeodomain

The homeodomain is a conserved motif composed of 4 helices. The structure includes a loop between helices 1 and 2 as well as a turn between helices 2 and 3. Helices 3 and 4 are separated by few residues and are often schematically drawn as a single helix, as in the adjacent diagram. Helices 3 and 4 lie in the major groove and interact with the DNA nucleotides [2].

(Image adapted from <http://www.uic.edu/classes/bios/bios100/lecturesf04am/lect15.htm> University of Illinois at Chicago)

2. Role of homeobox genes in human development and disease

Although homeobox genes were first identified in *Drosophila* [39] they have since been identified in fungi, plants and other eukaryotes [2]. In vertebrates, many homeobox genes are localized in genomic arrays called Hox clusters. Humans and other vertebrate species have four Hox clusters (A-D) that each contain 9-11 genes [47, 48]. The expression pattern of these genes along the anterior-posterior body axis of many different organisms (humans, fly, mice, zebrafish, etc) is collinear with their position in the genome [48]. Non-clustered homeobox genes (Para Hox) form families that are characterized by similarities within their homeodomain sequences as well as the presence of conserved domains flanking the homeodomain [49]. Examples of these families include the *Lim*, *Pax* and *Six* families that contain LIM, paired box (PAX) and SIX domains, respectively, in addition to their homeodomains [43, 49].

3. Cellular role of homeobox genes

Homeodomain proteins regulate many diverse cellular processes including differentiation, proliferation, apoptosis, migration and overall body patterning [47, 50]. Deregulated homeodomain protein expression has been implicated in different pathological conditions such as vascular disease and the development/progression of cancer [47, 51, 52]. Alterations in homeodomain protein expression can take many forms including the reactivation of developmental genes, the silencing of genes usually expressed in the adult and the activation of genes not normally expressed in a given tissue [49].

IV) Mesenchyme homeobox genes

1. Conservation of *Meox* genes during evolution

Murine *Meox1* (Mesenchyme Homeobox Gene), the first orthologue identified, encodes a 254 amino acid protein [53]. *Meox2*, the only other *Meox* homeobox family member identified, is slightly larger at 303 amino acids and has a predicted molecular weight of 33.6 kDa [54]. These proteins are 95% identical and 100% similar in their homeodomain sequences but have significantly diverged in regions which surround their homeodomains (Figure 3) [53, 54]. The *Meox1/2* genes share a similar genomic organization which includes three exons and two introns and they are not linked to any of the Hox clusters [53-55]. *Meox2* also contains a region rich in histidine and glutamine residues known as a CAX repeat (Figure 4) [54, 55]. Similar sequences, also called *opa* sequences, have been shown to be important in the transactivation function of other transcription factors such as HB24, Notch and HOX-11, although its function in *Meox2* is still unknown [56-58]. In our lab we have found that *Meox2* is a stronger transcriptional